Literature DB >> 3117447

Additive effects of growth hormone releasing factor and insulin hypoglycaemia on growth hormone release in man.

M D Page1, H P Koppeschaar, C A Edwards, C Dieguez, M F Scanlon.   

Abstract

We have measured GH and PRL changes following separate and combined administration of insulin and GH releasing factor (GRF) in six normal males. Peak GH responses to separate administration of insulin and GRF were comparable (71.4 +/- 10.2 vs 70.1 +/- 27.7 mU/l; mean +/- SEM). However, the peak GH response following combined administration was significantly higher (120.8 +/- 29.7, P less than 0.05) as was the total GH released as calculated by measuring the area under the curve (P less than 0.05). In contrast the PRL response to hypoglycaemia was not altered by the combined administration of insulin and GRF. This effect was not due to any direct action of hypoglycaemia or insulin at pituitary level since basal and 10(-8) M GRF stimulated GH release from rat anterior pituitary cells in vitro was not influenced by varying glucose and insulin levels. Our findings support the hypothesis that GRF and insulin-induced hypoglycaemia release GH via different pathways which are, at least in part, additive.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117447     DOI: 10.1111/j.1365-2265.1987.tb00814.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Growth hormone release during insulin tolerance, clonidine, arginine and growth hormone releasing hormone tests in short normal children and adolescents.

Authors:  L Cavallo; A Acquafredda; S Liuzzi; R Russo; C Zecchino; R Leuzzi; T Giobbe; L Piacente
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

Review 2.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

3.  The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.

Authors:  M L Drent; H J Adèr; E A van der Veen
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

4.  Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.

Authors:  A E Pontiroli; R Lanzi; L D Monti; G Pozza
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

5.  The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension.

Authors:  P Limone; S E Oleandri; P Ajmone Catt; S Grottoli; C Frangioni; E Avogadri; M Perrin; M R Valetto; M Maccario
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

6.  Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.

Authors:  C A Jaffe; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.